📊 BDTX Key Takeaways
Is Black Diamond Therapeutics, Inc. (BDTX) a Good Investment?
Black Diamond Therapeutics is a pre-revenue biotech company with zero revenue generation, negative operating cash flow of -$10.2M, and deteriorating profitability. At current burn rates, the company has approximately 3 quarters of cash runway remaining ($30.1M / ~$10.2M quarterly burn), creating near-term funding pressure without demonstrated commercial progress.
Black Diamond Therapeutics shows unusually strong near-term fundamentals for a development-stage biotech, with positive operating income, net income, and free cash flow alongside a debt-free balance sheet and very high liquidity. However, the quality and durability of those earnings appear less certain given limited revenue visibility, no gross margin disclosure, and the likelihood that reported profitability may depend on episodic collaboration or licensing activity rather than a broad recurring commercial base.
Black Diamond Therapeutics, Inc. Key Strengths (BDTX)
- Strong liquidity position with 8.46x current ratio providing short-term financial flexibility
- Low leverage with 0.00x debt-to-equity ratio minimizing financial distress risk
- Positive stockholders' equity of $104.3M providing some balance sheet cushion
- Debt-free capital structure with strong liquidity, including an 8.42x current ratio and substantial equity relative to liabilities
- Positive operating cash flow and free cash flow of $29.61M indicate the company is not currently dependent on external financing for operations
- Net income rose 132.1% YoY and profitability metrics are strong, with 17.9% operating margin and 32.0% net margin
BDTX Stock Risks: Black Diamond Therapeutics, Inc. Investment Risks
- Zero revenue with no path to profitability visible in current fundamentals
- Accelerating cash burn rate of -$10.2M per quarter with limited runway before capital depletion
- Highly dilutive capital structure evidenced by negative diluted EPS of -$0.16, destroying shareholder value
- Typical biotech funding risk requiring additional capital raises likely to dilute existing shareholders
- Revenue quality is unclear because YoY revenue growth and gross profit are unavailable, making sustainability harder to assess
- Profitability may be driven by non-recurring biotech partnership, licensing, or accounting items rather than durable operating leverage
- Cash balance of $20.99M is modest relative to the capital needs typical for biotech R&D, so future cash burn trends remain critical
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway
- Time to first revenue generation or clinical milestone announcements
- Capital raise requirements and dilution impact
- Operating expense trends and burn rate trajectory
- Operating cash flow consistency across future periods
- Revenue composition and recurring vs. one-time sources
Black Diamond Therapeutics, Inc. (BDTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.46x current ratio provides a solid financial cushion.
BDTX Profit Margin, ROE & Profitability Analysis
BDTX vs Healthcare Sector: How Black Diamond Therapeutics, Inc. Compares
How Black Diamond Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Black Diamond Therapeutics, Inc. Stock Overvalued? BDTX Valuation Analysis 2026
Based on fundamental analysis, Black Diamond Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Black Diamond Therapeutics, Inc. Balance Sheet: BDTX Debt, Cash & Liquidity
BDTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Black Diamond Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.27 indicates the company is currently unprofitable.
BDTX Revenue Growth, EPS Growth & YoY Performance
BDTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$9.0M | $-0.16 |
| Q3 2025 | N/A | -$8.5M | $-0.15 |
| Q2 2025 | N/A | -$10.6M | $-0.19 |
| Q1 2025 | N/A | -$18.2M | $-0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Black Diamond Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
BDTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Black Diamond Therapeutics, Inc. (CIK: 0001701541)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDTX
What is the AI rating for BDTX?
Black Diamond Therapeutics, Inc. (BDTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDTX's key strengths?
Claude: Strong liquidity position with 8.46x current ratio providing short-term financial flexibility. Low leverage with 0.00x debt-to-equity ratio minimizing financial distress risk. ChatGPT: Debt-free capital structure with strong liquidity, including an 8.42x current ratio and substantial equity relative to liabilities. Positive operating cash flow and free cash flow of $29.61M indicate the company is not currently dependent on external financing for operations.
What are the risks of investing in BDTX?
Claude: Zero revenue with no path to profitability visible in current fundamentals. Accelerating cash burn rate of -$10.2M per quarter with limited runway before capital depletion. ChatGPT: Revenue quality is unclear because YoY revenue growth and gross profit are unavailable, making sustainability harder to assess. Profitability may be driven by non-recurring biotech partnership, licensing, or accounting items rather than durable operating leverage.
What is BDTX's revenue and growth?
Black Diamond Therapeutics, Inc. reported revenue of $0.0.
Does BDTX pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
Where can I find BDTX SEC filings?
Official SEC filings for Black Diamond Therapeutics, Inc. (CIK: 0001701541) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDTX's EPS?
Black Diamond Therapeutics, Inc. has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BDTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Black Diamond Therapeutics, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BDTX stock overvalued or undervalued?
Valuation metrics for BDTX: ROE of -8.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BDTX's AI grade for 2026?
Our dual AI analysis gives Black Diamond Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDTX's free cash flow?
Black Diamond Therapeutics, Inc.'s operating cash flow is $-10.2M, with capital expenditures of $0.0.
How does BDTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -8.7% (avg: 15%), current ratio 8.46 (avg: 2).